Anna Dorottya Doleschall

Anna Dorottya Doleschall

Auto-generated profile, based on publicly available information

Anna Dorottya Doleschall

Medizinische Klinik IV, Uniklinik RWTH Aachen, Aachen, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2017 in Analytical Methods
Verified
Journal Article
Open access
PDF file
ZSZsuzsanna Szeitner
Zsuzsanna Szeitner
ADAnna Doleschall
Anna Doleschall
MVMarina Varga
Marina Varga
KKKatalin Keltai
Katalin Keltai
KRKatalin Révész
Katalin Révész
TMTamás Mészáros
Tamás Mészáros
We demonstrate the first application of a nuclease resistant aptamer, the so-called Spiegelmer, in a sandwich-type affinity assay by quantitative assessment of cardiac Troponin I (cTnI) in blood serum samples.

18 August 2026 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
DKDesiree Kunadt
Desiree Kunadt
SZSven Zukunft
Sven Zukunft
CRChristoph Röllig
Christoph Röllig
SMStephan Metzelder
Stephan Metzelder
ABAndreas Burchert
Andreas Burchert
F(for the German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)
for the German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.